Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

BACKGROUND: CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events following acute coronary syndrome. This phase 2a, randomized, double-blind, multicenter, dose-ranging trial represents the first clinical investigation to assess the safety an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Tricoci, Pierluigi, D’Andrea, Denise M, Gurbel, Paul A, Yao, Zhenling, Cuchel, Marina, Winston, Brion, Schott, Robert, Weiss, Robert, Blazing, Michael A, Cannon, Louis, Bailey, Alison, Angiolillo, Dominick J, Gille, Andreas, Shear, Charles L, Wright, Samuel D, Alexander, John H
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599471/
https://ncbi.nlm.nih.gov/pubmed/26307570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002171
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados